Momenta Pharmaceuticals,Inc. (NASDAQ:MNTA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ME Staff 8-k
-
0

Momenta Pharmaceuticals,Inc. (NASDAQ:MNTA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March7, 2018, the Board of Directors (the “Board”) of Momenta Pharmaceuticals,Inc. (the “Company”) approved the amendment and restatement of the Company’s 2013 Incentive Award Plan (the “Amended and Restated 2013 Plan”), subject to and effective upon stockholder approval. At the Company’s 2018 Annual Meeting of Stockholders, held on June20, 2018 (the “Annual Meeting”), stockholders approved the Amended and Restated 2013 Plan. The Amended and Restated 2013 Plan increases the number of shares of common stock available for issuance under the Amended and Restated 2013 Plan by 1,000,000 shares. For a description of the terms and conditions of the Amended and Restated 2013 Plan, see “Summary of the Amended and Restated 2013 Plan” under “Proposal Four—Approval of Amendment and Restatement of Momenta Pharmaceuticals,Inc. 2013 Incentive Award Plan” in the Company’s Proxy Statement filed with the Securities and Exchange Commission on April27, 2018, for the Annual Meeting (the “Proxy Statement”), which description is incorporated by reference.

Item 5.07 Submission of Matters to a Vote of Security Holders.

The Company’s Annual Meeting was held on June20, 2018. Of the 77,447,087 shares of the Company’s common stock entitled to vote, 71,415,395 shares were present in person or by proxy at the Annual Meeting. The matters voted on at the Annual Meeting, and the voting results for each matter, were as follows:

1. The stockholders elected each of the three ClassII nominees to the Company’s Board of Directors to hold office until the 2021 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified or until their respective deaths, resignations or removals.

For

Against

Abstain

BrokerNon- Votes

Jose-Carlos Gutierrez-Ramos

66,059,940

283,246

6,394

5,065,815

James R. Sulat

63,450,920

2,892,319

6,341

5,065,815

Craig A. Wheeler

66,074,549

258,700

16,331

5,065,815

2. The stockholders ratified the appointment of Ernst& Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December31, 2018.

For:

69,093,884

Against:

2,299,984

Abstain:

21,527

3. The stockholders approved on an advisory, non-binding basis the compensation of the Company’s named executive officers.

For:

64,082,753

Against:

2,184,475

Abstain:

82,352

Broker Non-Votes:

5,065,815

4. The stockholders approved the amendment and restatement of the Momenta Pharmaceuticals,Inc. 2013 Incentive Award Plan.

For:

63,480,922

Against:

2,850,119

Abstain:

18,539

Broker Non-Votes:

5,065,815


About Momenta Pharmaceuticals,Inc. (NASDAQ:MNTA)

Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox (enoxaparin sodium injection). Its GLATOPA is a generic version of once-daily COPAXONE 20 milligrams/milliliter (mg/mL) indicated for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS), a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. It is developing M923, which is a biosimilar of HUMIRA and M834 as a biosimilar of ORENCIA. Its oncology product candidate Necuparanib, is an oncology product candidate, which have a range of effects on tumor cells and the environment, in which tumor cells grow. It focuses on M281, which is an Anti-FcRn program.